Schizophrenia Drugs Market by Therapeutic Class - Global Industry Analysis and Forecast to 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 100 Pages

Description

Industry Outlook and Trend Analysis

The Schizophrenia Drugs Market was worth USD 6.35 billion in the year of 2014 and is expected to reach approximately USD 8.04 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 2.65% during the forecast period. Schizophrenia is a chronic disorder of the central nervous system, influences 1.0% of the worldwide populace or seven out of 1,000 people. The confusion portrayed by side effects, for example, thought disorders, hallucinations, inability to execute day-to day functions is known to develop from a combination of chemical, environmental and genetic factors. Rising number of patients looking for treatment and rising interest for enhanced healthcare infrastructure are foreseen to drive the market. The schizophrenia market stays packed with solid neglected needs. There is a requirement for advancement for the treatment of this crippling disorder. The report examines about developing markets in the Asia Pacific region. India and China are rising as an open door for market extension. Factors, for example, useful medicinal services, increased health awareness, large aging population, and low-cost are the real driving variables for market extension in these two nations.



Therapeutic Class Outlook and Trend Analysis

The drugs that are prescribed for schizophrenia can be fragmented by therapeutic class into first, second and third-generation antipsychotics. Presently, second-generation and third-generation antipsychotics remain the standard of care in the schizophrenia treatment market. The report features brands recommended for the treatment of schizophrenia, for example, Saphris, Zyprexa, Abilify, Seroquel, Vraylar, Saphris, Aristada, Fanapt among others. Long-Acting Injectables (LAIs) are progressively being produced as they offer a few points of interest, for example, diminished hospitalizations and enhanced treatment result. The variables limiting the development of worldwide schizophrenia drugs market would be strict control around new product endorsements and rising generic dispatches.

Regional Outlook and Trend Analysis

Japan is assessed to encounter the speediest development over the conjecture time frame because of enhanced healthcare infrastructure, increasing awareness about early diagnosis, rising disposable income, and accessibility of successful treatment. The worldwide schizophrenia drugs market will be driven by the developing awareness about mental issue, expanded use on medicinal services and accessibility of powerful treatment strategies with interest for tailored and target specific medications.

Competitive Insights

The leading players in the market are Eli Lilly and Company, Bristol-Myers Squibb, Dainippon Sumitomo Pharma Co Ltd, Vanda Pharma, Johnson & Johnson, Alkermes, Allergan and AstraZeneca. Johnson & Johnson, Otsuka and Lundbeck are concentrating on developing the schizophrenia therapeutics market for Long-Acting Injectables and are anticipated to possess tremendous position in the schizophrenia therapeutics market.

The Schizophrenia Drugs Market is segmented as follows-

By Therapeutic Class:


Second-Generation Antipsychotics


Invega (Paliperidone)
Geodon (Ziprasidone)
Latuda (Lurasidone)
Fanapt (Iloperidone)
Vraylar (Cariprazine)
Risperdal (Risperidone)
Zyprexa (Olanzapine)
Seroquel (Quetiapine)
Aristada (Aripiprazole Lauroxil)
Saphris (Asenapine)


Third-Generation Antipsychotics

Abilify (Aripiprazole)


Others

Generics
First-Generation Antipsychotics




By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2015 to 2023`
What will be the industry market growth from 2015 to 2023`
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

1. Introduction

1.1. Report Description

1.2. Research Methodology

1.2.1. Secondary Research

1.2.2. Primary Research

2. Executive Summary

2.1. Key Highlights

3. Market Overview

3.1. Introduction

3.1.1. Market Definition

3.1.2. Market Segmentation

3.2. Market Dynamics

3.2.1. Drivers

3.2.1.1. Rising Demand for Improved Healthcare Infrastructure

3.2.1.2. Growing Health Awareness

3.2.2. Restraints

3.2.2.1. Availability of Low Cost Substitute

3.2.3. Opportunities

3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities

4. Schizophrenia Drugs Market,By Therapeutic Class

4.1. Introduction

4.2. Schizophrenia Drugs Market Assessment and Forecast, By Therapeutic Class, 2014-2023

4.3. Second-Generation Antipsychotics

4.3.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.3.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.3. Invega (Paliperidone)

4.3.3.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.4. Geodon (Ziprasidone)

4.3.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.5. Latuda (Lurasidone)

4.3.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.6. Fanapt (Iloperidone)

4.3.6.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.7. Vraylar (Cariprazine)

4.3.7.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.8. Risperdal (Risperidone)

4.3.8.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.9. Zyprexa (Olanzapine)

4.3.9.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.10. Seroquel (Quetiapine)

4.3.10.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.11. Aristada (Aripiprazole Lauroxil)

4.3.11.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.3.12. Saphris (Asenapine)

4.3.12.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.4. Third-Generation Antipsychotics

4.4.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.4.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.4.3. Abilify (Aripiprazole)

4.4.3.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5. Others

4.5.1. Market Assessment and Forecast, By Type, 2014-2023 ($Million)

4.5.2. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5.3. Generics

4.5.3.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5.4. First-Generation Antipsychotics

4.5.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5. Schizophrenia Drugs Market,By Region

5.1. Introduction

5.2. Schizophrenia Drugs Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.3. North America

5.3.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.3.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.3. U.S.

5.3.3.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.4. Canada

5.3.4.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.3.5. Mexico

5.3.5.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4. Europe

5.4.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.4.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.3. Germany

5.4.3.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.4. France

5.4.4.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.5. UK

5.4.5.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.6. Italy

5.4.6.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.7. Spain

5.4.7.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.4.8. Rest of Europe

5.4.8.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5. Asia-Pacific

5.5.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.5.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.3. Japan

5.5.3.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.4. China

5.5.4.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.5. Australia

5.5.5.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.6. India

5.5.6.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.7. South Korea

5.5.7.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.5.8. Rest of Asia-Pacific

5.5.8.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6. Rest of the World

5.6.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

5.6.2. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.3. Brazil

5.6.3.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.4. Turkey

5.6.4.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.5. Saudi Arabia

5.6.5.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.6. South Africa

5.6.6.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.7. United Arab Emirates

5.6.7.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

5.6.8. Others

5.6.8.1. Market Assessment and Forecast, By Therapeutic Class, 2014-2023 ($Million)

6. Company Profiles

6.1. Johnson & Johnson

6.1.1. Business Overview

6.1.2. Product Portfolio

6.1.3. Key Financials

6.1.4. Strategic Developments

6.2. Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals

6.2.1. Business Overview

6.2.2. Product Portfolio

6.2.3. Key Financials

6.2.4. Strategic Developments

6.3. AstraZeneca

6.3.1. Business Overview

6.3.2. Product Portfolio

6.3.3. Key Financials

6.3.4. Strategic Developments

6.4. Eli Lilly

6.4.1. Business Overview

6.4.2. Product Portfolio

6.4.3. Key Financials

6.4.4. Strategic Developments

6.5. Alkermes

6.5.1. Business Overview

6.5.2. Product Portfolio

6.5.3. Strategic Developments

6.6. Sumitomo Dainippon Pharma

6.6.1. Business Overview

6.6.2. Product Portfolio

6.6.3. Strategic Developments

6.7. Pfizer

6.7.1. Business Overview

6.7.2. Product Portfolio

6.7.3. Strategic Developments

6.8. Vanda Pharmaceuticals

6.8.1. Business Overview

6.8.2. Product Portfolio

6.8.3. Strategic Developments

6.9. Allergan (Forest Labs)/ Geodon Ritcher

6.9.1. Business Overview

6.9.2. Product Portfolio

6.9.3. Key Financials



6.9.4. Strategic Developments


Table of Figures

Table 1.Schizophrenia Drugs Market, By Therapeutic Class ($Million), 2014-2023
Table 2.Second-Generation Antipsychoticsl Market, By Type ($Million), 2014-2023
Table 3.Second-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 4.Invega (Paliperidone) Market, By Region ($Million), 2014-2023
Table 5.Geodon (Ziprasidone) Market, By Region ($Million), 2014-2023
Table 6.Latuda (Lurasidone) Market, By Region ($Million), 2014-2023
Table 7.Fanapt (Iloperidone) Market, By Region ($Million), 2014-2023
Table 8.Vraylar (Cariprazine) Market, By Region ($Million), 2014-2023
Table 9.Risperdal (Risperidone) Market, By Region ($Million), 2014-2023
Table 10.Zyprexa (Olanzapine) Market, By Region ($Million), 2014-2023
Table 11.Seroquel (Quetiapine) Market, By Region ($Million), 2014-2023
Table 12.Aristada (Aripiprazole Lauroxil) Market, By Region ($Million), 2014-2023
Table 13.Saphris (Asenapine) Market, By Region ($Million), 2014-2023
Table 14.Third-Generation Antipsychotics Market, By Type ($Million), 2014-2023
Table 15.Third-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 16.Abilify (Aripiprazole) Market, By Region ($Million), 2014-2023
Table 17.Others Market, By Type ($Million), 2014-2023
Table 18.Others Market, By Region ($Million), 2014-2023
Table 19.Generics Market, By Region ($Million), 2014-2023
Table 20.First-Generation Antipsychotics Market, By Region ($Million), 2014-2023
Table 21.North America Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 22.North America Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 23.U.S.Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 24.Canada Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 25.Mexico Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 26.Europe Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 27.Europe Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 28.Germany Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 29.France Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 30.UK Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 31.Italy Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 32.Spain Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 33.Rest of Europe Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 34.Asia-Pacific Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 35.Asia-Pacific Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 36.Japan Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 37.China Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 38.Australia Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 39.India Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 40.South Korea Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 41.Rest of Asia-Pacific Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 42.Rest of the World Schizophrenia Drugs Market, By Country, 2014-2023 ($Million)
Table 43.Rest of the World Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 44.Brazil Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 45.Turkey Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 46.Saudi Arabia Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 47.South Africa Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 48.United Arab Emirates Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 49.Others Schizophrenia Drugs Market, By Therapeutic Class, 2014-2023 ($ Million)
Table 50.Johnson & Johnson: Key Strategic Developments, 2015-2017
Table 51.Bristol-Myers Squibb and Company/ Otsuka Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 52.AstraZeneca: Key Strategic Developments, 2015-2017
Table 53.Eli Lilly: Key Strategic Developments, 2015-2017
Table 54.Alkermes: Key Strategic Developments, 2015-2017
Table 55.Sumitomo Dainippon Pharma: Key Strategic Developments, 2015-2017
Table 56.Sumitomo Dainippon Pharma: Key Strategic Developments, 2015-2017
Table 57.Vanda Pharmaceuticals: Key Strategic Developments, 2015-2017
Table 58.Allergan (Forest Labs)/ Geodon Ritcher: Key Strategic Developments, 2015-2017

Request Sample

* mark fields are compulsory